



## Emerging Advances in Neuropharmacology: Novel Therapeutic Targets for Neurodegenerative Disorders

<sup>1</sup>Sumairah Qadir, <sup>1</sup>Nisha\*

<sup>1</sup> Department of Pharmacology, School of Pharmacy, Desh Bhagat University, Mandi Gobindgarh, Punjab, India.

### Keywords

Neuropharmacology,  
Neurodegenerative  
disorders, Alzheimer's  
disease, Parkinson's  
disease,  
Neuroinflammation,  
Protein misfolding,  
Disease-modifying  
therapies.

### Abstract

Neurodegenerative diseases are a heterogeneous group of chronic and progressive disorders, which are characterized by selective neuronal destruction, synaptic malfunction and progressive cognitive and locomotor dysfunction. The major ones are Alzheimer disease, Parkinson disease, Huntington disease, and amyotrophic lateral sclerosis which are a formidable and growing global health and socio-economic burden mainly due to demographic aging. Even despite the advances in the symptomatic treatment, predominantly through the cholinergic, dopaminergic, glutamatergic, and GABAergic system, the current treatment regimens are not able to stop the underlying neurodegenerative events or reverse them. There is mounting evidence that convergent pathogenic mechanisms, such as protein misfolding and aggregation, oxidative stress, mitochondrial dysfunction, impaired autophagy-lysosomal pathways, synaptic dysfunction, and chronic neuroinflammation, are convergent mechanisms. These convergent molecular and cellular cascades provide a strong rationale behind the identification of new neuropharmacological targets, which include: kinases, phosphatases, epigenetic regulators, neurotrophic signalling pathways and neuroimmune mediators. Advances in the biomarker discovery, genomics and systems biology have further enabled the use of precision based therapeutic stratification and early-intervention approaches. Genetic, nanotechnology, and RNA-based therapeutics as well as biologics are reconfiguring translational models in neurodegeneration. A mechanism-based, multi-target, precision neuropharmacological approach, as a group, has significant potential in achieving long-term neuroprotection, improved clinical and disease modification in neurodegenerative diseases.

### \*Corresponding Author:

Ms. Nisha ([shaarmanishii8@gmail.com](mailto:shaarmanishii8@gmail.com))

### Article Info

Received: 29 March 2026, Received in revised form: 28 July 2026, Accepted: 28 July 2026, Available online: 30 July 2026; Volume: 2; Issue: 2; Pages: 271–291.

ISSN: 3049-2955/The authors © 2026, under exclusive license to the Sprout Publication

DOI: <https://doi.org/10.63785/2026.2.2.271291>

## 1. Introduction

### 1.1 Neurodegenerative Disorders: Scope and Clinical Impact

The neurodegenerative disorders are a heterogeneous continuum of chronic, progressive pathological entities, which are seen to be the result of gradual and selective neuronal loss in the central and peripheral nervous systems. Significant and growing health burden on the world population is manifested by major entities, including Alzheimer disease, Parkinson disease, Huntington disease, amyotrophic lateral sclerosis, and multiple sclerosis [1]. The problem of these disorders is increasing steadily, which is, in large part, due to the changes of the

demographic structure towards the aging population, and is linked to an increase in morbidity, mortality, and long-term disability on a global scale [2]. Neurodegeneration is clinically expressed in form of progressive cognitive deterioration, motor dysfunction, sensory disturbances and behavioural aberrations with the end result of loss of functional independence and worsening of the overall quality of life [3].

In addition to their clinically manifested conditions, neurodegenerative disorders cause a significant socioeconomic cost to the patients, their caregivers,

and health care systems. The long-term care needs, reduced productivity and increased spending on health care have a significant effect [4]. Although the clinical phenotype of many neurodegenerative diseases is highly heterogeneous, they all overlap on common pathogenic pathways, such as protein misfolding and aggregation, mitochondrial impairment, oxidative stress, synaptic impairment and chronic Neuroinflammation [5]. The heterogeneous, multifactorial etiologies of these disorders make it difficult to identify them early and elicit the creation of effective interventions, which further highlights the need to better understand the mechanisms of the disease and to develop more effective disease-modifying therapeutic interventions [6].

### 1.2 Current Therapeutic Landscape and Unmet Needs

The present paradigms of treatment in neurodegenerative diseases are mostly focused on the amelioration of the symptoms and not on the cure of the diseases. Pharmacological treatments such as cholinesterase inhibitors and NMDA receptor antagonists of Alzheimer disease or dopaminergic treatments of Parkinson disease are approved and provide temporary relief of cognitive or motor impairments but do not prevent the progressive loss of neurons [7]. Such therapies have relatively low clinical efficacies, which reduce with continued use and are regularly limited by side effects that reduce patient compliance. Although considerable research efforts have been made, the translation of promising preclinical candidates into effective clinical interventions has not been fulfilled with many agents not showing improvement in their advanced-phase trials [8]. Thus, there is a strong unsatisfied need of therapeutics that would act on early and central pathogenic mechanisms, demonstrated sustained effectiveness, and enhanced clinical outcome in the long run. The need to deal with heterogeneity of diseases using biomarker-directed and precision medicine approaches is also essential to add to disease therapeutic response, as well as to improve patient care [9].

### 1.3 Rationale for Novel Neuropharmacological Targets

The ineffective nature of current treatment of neurodegenerative disorders underscores the imperative need to identify and confirm new neuropharmacological targets which resonate with fundamental disease pathology [10]. It has been demonstrated that neurodegeneration has a multicomponent etiology near protein misfolding, autophagy dysregulation, mitochondrial impairment, synaptic loss, and sustained neuroinflammation

through recent advances in molecular biology and systems neuroscience. Such intervention in these pathways has the potential to alter the course of the disease and not just to diminish the symptoms [11]. The involvement of non-neuronal cell types, such as microglia and astrocytes is also becoming increasingly engaged, thus, showing other potential therapeutic points of interest that are not limited to the conventional neuron-focused paradigms [12]. Besides, the combination of genomics, proteomics, and biomarker discovery has made the identification of targets and stratification of patients more precise. Taken together, these developments justify a paradigm shift of going towards mechanism-based, multi-target, precision neuropharmacological approaches that will result in sustained neuroprotection and improvements in clinical outcomes [13].

## 2. Fundamentals of Neuropharmacology in Neurodegeneration

Neuropharmacology in the area of neurodegeneration aims to explain how the pharmacological agonists may interact with neurons and non-neurons to change the progression of disease and clinical presentation [14]. This research brings together a perception of neurotransmitter networks, receptor-based signalling pathways, intracellular mechanisms, and neuroimmune processes that when combined together, affect neuronal survival and disease [15]. In neurodegenerative pathologies the therapeutic interventions will be aimed to restore the synaptic homeostasis, mitigate the neurotoxic processes, and protect the vulnerable neural circuitry [16]. The understanding of the efficacy and safety of neurotherapeutic agents cannot be achieved without a comprehensive understanding of the permeability of the blood-brain barrier, target specificity, and pharmacodynamic correlates of pharmacokinetics [17].

### 2.1 Neurotransmission and Synaptic Homeostasis

Neurotransmission is a highly controlled biophysical process through which intercellular communication occurs within the brain through controlled release, uptake, and deactivation of chemical/electrical signals at the synaptic junction. It is based on high fidelity excitatory and inhibitory transmitter activity, fine-tuning of the receptor dynamics, and the efficacy of vesicular transport processes all of which are essential towards optimal synaptic performance [18]. In neurodegenerative pathophysiology, alterations in neurotransmitter biosynthesis, vesicular exocytosis, or receptor-mediated signalling result in impaired synaptic plasticity and dysfunctioning of a network of

neurons in general [19]. The changes in glutamatergic, cholinergic, dopaminergic, and GABAergic pathways can often appear, and these alterations are used to manifest the development of initial cognitive and motor impairments before the severe loss of neurons [20].

Synaptic homeostasis refers to the collection of processes that maintain a constant neural activity in the wake of chronic physiological and pathological challenges. Such mechanisms include scaling of activity dependent synapses, receptor trafficking and reactions to intracellular signalling pathways [21]. Neurodegenerative disease is associated with dysfunction of synaptic homeostasis that induces excitotoxicity, abnormal synaptic pruning, and disequilibrium of the circuit. Based on this, the maintenance of synaptic health and the restoration of neurotransmission balance in the brain have become the primary goals of neuropharmacology, meant to slow the progression of the disease and improve functional performance [22].

## **2.2 Blood–Brain Barrier and CNS Drug Delivery**

The blood-brain barrier (BBB) is one of the most exquisitely specialized, selectively permeable boundaries, which maintains homeostasis of the central nervous system (CNS) by strictly controlling the exclusion of solutes between the systemic circulation and the neuro-parenchymal area [23]. The physical wall is established structurally through endothelial cells connected to each other by tight junctions, and astrocytic end- feet and pericytes, and that as a unit, act to limit the entry of potentially harmful substances. This protective architecture, therefore, constitutes a serious impediment to neuropharmacological intervention with many therapeutic agents exhibiting, either low lipid solubility, high molecular weight or serving as substrates of active efflux transporters [24]. The therapeutic delivery of therapeutics to the central nervous system requires the successful methods to overcome or take advantage of the properties of the blood brain barrier (BBB) and maintain its structure [25]. There are strategies that encompass chemical modification of pharmacologic agents, exploitation of carrier-mediated transport systems, nanoparticle-based delivery systems, and receptor-mediated transcytosis, which may increase cerebral drug bioavailability [26]. However, the issue of optimization of BBB permeability without losing the safety aspect is a critical aspect in the design of effective therapeutic agents against neurodegenerative pathologies [27].

## **2.3 Challenges in Target Identification and**

### **Validation**

The pathology of neurodegenerative diseases is multifactorial and heterogeneous, which hinders the identification of targets. Protein aggregation, neuroinflammation, mitochondrial dysfunction, and synaptic failure are concomitant molecular pathways that occur in parallel and therefore promote the progression of disease [28]. Distinguishing between primary causal drivers and secondary or compensatory changes has been daunting especially when taking into account the dynamic changes in pathology of different disease stages [29]. Furthermore, the restrictions associated with model experimental procedures do not often entirely simulate human pathological neurodegenerative states, thus reducing the translational value of preclinical research [30].

Target validation presents further complications, as the modulation of a single molecular target does not usually induce clinically relevant benefit. Indirect toxicity (off-target effect), pathway and species orthogony can compromise the safety and efficacy of therapy [31]. In addition, the lack of reliable biomarkers to detect target engagement and predict clinical outcomes is also a hindrance to effective translational progression. In that regard, effective validation systems, which involve human-relevant models, longitudinal biomarker profiling, and system analyses are essential to successful neuropharmacological target development [32].

## **3. Molecular and Cellular Mechanisms of Neurodegeneration**

A combination of molecular and cellular processes supporting neurodegeneration perturbs neuronal structure and functions [33]. The most important pathophysiological processes include protein misfolding, aggregation, mitochondrial impairments, oxidative stress, impaired autophagic flux, and calcium homeostasis [34]. These disease-inducing cascades result in dysfunction of synaptic functions, neuroinflammatory cascades and eventual cell death. The communication between neurons, the populations of glial cells, and the signalling through immune mediators further increases the damage of cells and the tissue loss [35]. The rational design of therapeutic interventions that may be used to reduce disease trajectory in neurodegenerative disorders is indispensable without a comprehensive understanding of these interrelated mechanisms [36].

### **3.1 Protein Misfolding and Aggregation**

Protein misfolding and aggregation are important pathological mechanisms of various neurodegenerative diseases such as Alzheimer

disease, Parkinson disease, Huntington disease, and amyotrophic lateral sclerosis [37]. Protein degradation can be maintained by closely regulated mechanisms of molecular chaperones, ubiquitin usually proteasome system and autophagy lysosome in physiological conditions. When these quality control mechanisms are perturbed, the misfolded proteins accumulate and form aberrant conformation and oligomers that form toxic aggregates and insoluble inclusions [38]. These aggregates include amyloid-2 plaques, tau neurofibrillary tangles, and alpha-synuclein Lewy bodies, and mutant huntingtin inclusions, which impair the normal functioning and synaptic signalling of cells [39].

Recent data are increasingly pointing to soluble oligomeric assemblies having a strong neurotoxic effect through destabilization of membrane integrity, calcium homeostasis, and control of intracellular signalling cascades [40]. Protein aggregates also overwhelm proteolytic pathways, cause oxidative stress, and cause persistent neuroinflammatory reactions through microglial and astrocytic stimulation [41]. Moreover, misfolded proteins are prone to spread in a prion-like manner spreading pathology across the interconnected neural systems. Together, these mechanisms contribute to the progressive neuronal impairment and death, hence supporting the protein misfolding and aggregation to be the key targets of disease-modifying neuropharmacological interventions [42].

### **3.2 Oxidative Stress and Mitochondrial Dysfunction**

The two processes oxidative stress and mitochondrial dysfunction are interdependent processes that play a central role in the pathogenesis of neurodegenerative disorders. Neurons are overly vulnerable to oxidative damage, which can be explained by the high rate of their metabolic activity and limited antioxidant protection [43]. Excessive production of reactive oxygen and nitrogen species induces lipid peroxidation, protein oxidation, and damage of the genome and thus reduces cellular integrity and functional ability of the synapses. The oxidative impairments promote the early neuronal dysfunction and increase cell susceptibility to subsequent degenerative processes [44].

The mitochondrial dysfunction also increases oxidative stress by interfering with ATP production, calcium homeostasis, and apoptotic levels of signalling. Damage in the electron transport chain increases the formation of the free radicals, which propagates a vicious circle of energetic failure and oxidative tissue damage [45]. Additionally, an unchecked aberrant mitochondrial dynamics and

mitophagic malformations result in the survival of non-functional organelles. In turn, the synergistic effect of oxidative stress and mitochondrial damage accelerates the process of neuronal degeneration, which explains the urgent need to implement interventions that will preserve mitochondrial integrity and preserve redox homeostasis in neuropharmacological systems [46].

### **3.3 Neuroinflammation and Glial Dysregulation**

Neuroinflammation is a highly noticeable and persistent phenotype of neurodegenerative diseases, which have their origins in the dysregulated stimulation of glial cells, in particular, microglia and astrocytes. In the physiological state, glial cells play fundamental roles in immune survey, synaptic aid and neuronal homeostasis preservation [47]. However, chronic microglial activation in pathological conditions leads to excessive release of pro-inflammatory cytokines, chemokines, and reactive oxygen species, and therefore synaptic dysfunction and neuronal injury. Astrocytic dysfunction also contributes to the disease progression by reducing metabolic support, neurotransmitter clearance as well as the integrity of the blood-brain barrier [48]. Continued disproportion of glial cells facilitates a poisonous inflammatory atmosphere which enhances neuronal harm and accelerates disease. In addition to causing direct neurotoxicity neuroinflammation impairs synaptic plasticity and promotes aberrant assemblage of proteins [49]. Recent studies indicate that neuroinflammatory processes could produce neuroprotection in the early stages but then lead to maladaptive changes on a long-term basis [50]. Based on this, glial activation attenuation and neuroimmune balance recovery will form a novel therapeutic paradigm to accelerate neurodegeneration and improve clinical outcomes [51].

### **3.4 Synaptic Dysfunction and Neuronal Loss**

Synaptic dysfunction is a primary and focal phenomenon in the pathogenesis of neurodegenerative diseases, and in many cases, precedes the loss of neurons. Changes in the integrity of synapses and dysregulation of neurotransmitter release together with defects in receptor signalling disrupt neural network connectivity and impair synaptic plasticity, which are also involved in the occurrence of cognitive and motor impairments [52]. The pathogenic factors such as misfolded protein oligomers, oxidative stress, and neuroinflammatory mediators directly hinder the process of synaptic transmission and enhance excitotoxicity. Synapses are especially vulnerable to these damaging attacks

given the high dynamism and metabolic activity of the synapse [53].

both apoptotic and necrotic processes. The degeneration of neurons is catalyzed as the neurons lose their synaptic input, which provides them with the necessary trophic support. Death of neurons, in its turn, induces even greater destabilization of neural networks and deterioration of functionality. As the synaptic loss is strongly correlated with the severity of the disease, the maintenance of synaptic integrity and inhibition of neuronal death are key points in the progress of disease-modifying treatments of neurodegenerative diseases [54].

The gradual loss of the synaptic integrity eventually leads to the permanent loss of neurons by activating


Table 1 summarizes the major molecular and cellular mechanisms underlying neurodegenerative disorders. It highlights key pathogenic events, including protein aggregation, oxidative stress, mitochondrial dysfunction, neuroinflammation, impaired proteostasis, and metabolic dysregulation, together with their pathological consequences and associated diseases. These interconnected pathways collectively drive progressive neuronal dysfunction, degeneration, and clinical disease progression [55].

**Table 1:** Major molecular and cellular mechanisms implicated in neurodegenerative disorders.

| Sr. No. | Mechanism                          | Representative Molecular Events              | Pathological Consequences         | Associated Disorders | References |
|---------|------------------------------------|----------------------------------------------|-----------------------------------|----------------------|------------|
| 1.      | Protein misfolding and aggregation | Aβ, tau, α-synuclein, huntingtin aggregation | Synaptic toxicity, neuronal death | AD, PD, HD           | [37]       |
| 2       | Oxidative stress                   | Excess ROS/RNS production                    | Lipid, protein, DNA damage        | AD, PD, ALS          | [56]       |
| 3.      | Mitochondrial dysfunction          | ETC impairment, ATP depletion                | Energy failure, apoptosis         | PD, AD, ALS          | [57]       |
| 4.      | Neuroinflammation                  | Chronic microglial/astrocytic activation     | Cytokine-mediated neurotoxicity   | AD, MS               | [58]       |
| 5.      | Autophagy–lysosomal dysfunction    | Impaired protein/organelle clearance         | Aggregate accumulation            | AD, PD               | [59]       |
| 6.      | Excitotoxicity                     | Excess glutamate, Ca <sup>2+</sup> influx    | Neuronal injury                   | ALS, HD              | [60]       |
| 7.      | Axonal transport defects           | Microtubule and motor protein disruption     | Synaptic degeneration             | AD, ALS              | [61]       |
| 8.      | Neurotrophic factor deficiency     | Reduced BDNF/NGF signalling                  | Loss of neuronal survival         | AD, PD               | [62]       |
| 9.      | Proteasome dysfunction             | Impaired ubiquitin–proteasome system         | Toxic protein buildup             | PD, AD               | [63]       |
| 10      | RNA metabolism defects             | Abnormal RNA splicing/transport              | Impaired protein synthesis        | ALS, FTD             | [64]       |
| 11.     | Epigenetic alterations             | DNA methylation, histone modification        | Aberrant gene expression          | AD, HD               | [65]       |
| 12.     | Insulin signalling impairment      | Brain insulin resistance                     | Synaptic failure                  | AD                   | [66]       |
| 13.     | Lipid metabolism dysregulation     | Cholesterol, sphingolipid imbalance          | Membrane instability              | AD                   | [67]       |
| 14.     | Prion-like propagation             | Cell-to-cell protein spread                  | Disease progression               | AD, PD               | [68]       |
| 15.     | Neurovascular unit dysfunction     | Impaired cerebral perfusion                  | Neuronal stress                   | AD, VaD              | [69]       |

Figure 1 illustrates the interconnected pathogenic mechanisms underlying neurodegenerative neuroinflammation, synaptic impairment, and genomic instability collectively disrupt neuronal homeostasis. These processes interact through multiple feedback loops, ultimately promoting

disorders. Amyloid and tau aggregation, oxidative stress, mitochondrial dysfunction, neuronal dysfunction, progressive neurodegeneration, and the clinical manifestations of disorders such as Alzheimer's and Parkinson's diseases [70].



**Figure 1:** Integrated molecular pathways contributing to neurodegeneration. Schematic representation of the interconnected molecular mechanisms underlying neurodegeneration, highlighting amyloid and tau pathology, mitochondrial dysfunction, oxidative stress, neuroinflammation, and synaptic impairment, which collectively contribute to progressive neuronal dysfunction and eventual neuronal death.

#### 4. Emerging Molecular Targets for Neuropharmacological Intervention

##### 4.1 Kinases, Phosphatases, and Signalling Pathways

Activation and inhibition of diverse intracellular signalling pathways implicated in regulating neuronal survival, synaptic plasticity and cellular homeostasis are controlled by kinases and phosphatases. These enzymes produce control over key cell processes, such as gene transcription, cytoskeleton, and regulation of the neurotransmitter receptor activity through the regulation of protein phosphorylation status. Disturbance of the kinasephosphatase balance is also a typical feature of neurodegenerative diseases and enables the survival of pathological signalling pathways [71].

Pathological phosphorylation of proteins, synaptic dysfunction, and neuronal death have been linked to aberrant activation of such kinases as glycogen

synthase kinase -3b, cyclin-dependent kinase -5, mitogen-activated protein kinases, and the mammalian target of rapamycin. On the other hand, reduced phosphatase activity, especially protein phosphatase-2A activity leads to the prolongation of hyperphosphorylation of disease-related proteins including tau hence speeding up neurodegenerative mechanisms [72].

Nevertheless, it is a logical approach to neuropharmacological treatment to target the signal pathways that are regulated by kinases and phosphatases. Specific modulation of these enzymes would be able to recapitulate signalling homeostasis, reduce aberrant protein changes and enhance neuronal resistance. This has prompted the active research of kinase- and phosphatase-based therapeutic interventions as disease-modifying in neurodegenerative diseases [71].

##### 4.2 Epigenetic and Transcriptional Regulators

The regulators of epigenetics and transcription have a central role in the regulation of gene expression programs which are critically important to the neurons and their plasticity and survival. Genetic alterations in DNA methylation, histone post-conveyance, mitochondrial biogenesis, and stress reaction pathways [73]. Together with epigenetic enzymes, e.g., histone deacetylases, DNA methyltransferases, and non-coding RNAs, transcription factors promote the progression of the disease by promoting maladaptive cell phenotypes. These regulators can be targeted to provide a therapeutic approach that allows reversible regulation of the expression of genes without altering the underlying genomic sequence [74]. As a result thereof, the epigenetic-based interventions can be considered as the promising pathways to restoring neuronal homeostasis as well as to the formation of disease-modifying neuropharmacological therapeutic options [75].

#### **4.3 Autophagy-Lysosomal and Proteostasis Targets**

The autophagy-lysosomal pathway is a cellular pathway of the paramount which maintains proteostasis through systematic breakdown and re-utilisation of misplaced proteins and defective organelles [76]. Disruption of this process is a characteristic of a continuum of neurodegenerative diseases, and the ultimate outcome is the accumulation of harmful proteinaceous aggregates and cellular distress [77]. Key molecular constituents which are identified in this framework include autophagy-related proteins, lysosomal hydrolases and orchestral controllers of vesicular trafficking and membrane fusion. Proteins also have an extra attenuation of proteasomes, which further enhances proteostatic breakdown, increasing the vulnerability of neurons [78]. Pharmacological correction of autophagy and lysosomal events is suggested to be an interesting approach to increase intracellular clearance, restore proteomic balance, and mitigate neurodegenerative consequences, which contributes to strengthening the potential of disease-modifying neurotherapy systems [79].


#### **4.4 Neurotrophic Factors and Survival Pathways**

Neurotrophic factors are also vital controllers of neuronal development, maintenance, and

translational alterations, and chromatin remodelling processes have steadily been linked with neurodegenerative illnesses leading to the erratic expression of genes that regulate synaptic

survivability whose actions are mediated through receptor-mediated signalling pathways. Signalling cascades of compounds such as brain-derived neurotrophic factor, nerve growth factors as well as glial cell lineage-derived neurotrophic factor form the basis of synaptic plasticity, axonal integrity, and cellular resistance to stress [80]. The impaired functioning of the nervous system in neurodegenerative pathologies is caused by the reduced availability or altered signalling of these factors. Neurotrophic receptors signal transduction cascades downstream, such as phosphoinositide 3-kinase/ Akt and mitogen activated protein kinase, have been shown to be required in promoting neuronal resilience and preventing cell death by apoptosis [81]. Interventions aimed to boost neurotrophic signalling, such as direct administration of neurotrophic factors or pharmacological regulation of downstream pathways, are fairly promising in terms of slowing down disease pathogenesis and being able to maintain neural activity [82].

Figure 2 depicts the complex interplay of molecular mechanisms underlying neurodegeneration. The accumulation of misfolded and aggregated proteins disrupts cellular homeostasis, while mitochondrial dysfunction impairs energy production and increases the generation of reactive oxygen species. Excessive oxidative stress further damages cellular components, including proteins, lipids, and DNA, thereby aggravating neuronal dysfunction. Concurrently, persistent neuroinflammation and dysregulated inflammatory signaling promote microglial and astrocytic activation, contributing to a sustained neurotoxic environment. Synaptic dysfunction and impaired neuronal communication further compromise cognitive and neurological functions. These pathological mechanisms are closely interconnected and can reinforce one another, creating a self-perpetuating cycle of neuronal injury. Collectively, these molecular disturbances accelerate neuronal degeneration, disrupt neuronal homeostasis, and contribute to the initiation and progression of diverse neurodegenerative disorders [83].



**Figure 2:** Novel and emerging molecular targets for neurodegenerative disorders. Schematic illustration depicting the central role of neuroinflammation in neurodegenerative disorders, highlighting the interplay between misfolded proteins, inflammatory signalling pathways, mitochondrial dysfunction, reactive oxygen species (ROS) generation, and neuronal damage, which collectively contribute to progressive neurodegeneration and impaired brain function.

## 5. Neurotransmitter- and Receptor-Based Therapeutic Targets

These neurotransmitter- and receptor-based targets focus on the recovery of the disrupted neurodegenerative disorder synaptic signalling. Cholinergic, dopaminergic, glutamatergic and GABAergic receptor modulation have been proven to improve cognitive and motor functioning. Although they mostly treat the symptoms, these objectives are the key elements of the multifaceted neuropharmacologic interventions [84].

### 5.1 Glutamatergic and GABAergic Systems

The glutamatergic system is the main excitatory pathway of neurotransmission in the central nervous system, and it is necessary in learning, memory, and synaptic plasticity. During neurodegenerative states, disruption of glutamate signalling leads to overstimulation of the receptors, dysregulation of calcium and excitotoxic death of neurons. Both ionotropic and metabotropic glutamate receptor dysfunctions have been well-supported by synaptic dysfunction and gradual neuronal loss [85].

GABAergic system is the major inhibitory control system that is needed to maintain exciter-inhibitor homeostasis in neural networks. Weakened GABAergic transmission or receptor dysfunction is likely to increase network hyperexcitability and predisposes to excitotoxic damage [86]. The clinical target of glutamatergic and GABAergic therapy aims at finding the balance of synapses, neuronal integrity, and improved functioning in neurodegenerative disease [87].

### 5.2 Cholinergic and Dopaminergic Modulation

Cholinergic system is a key part of higher cognitive processes, which entail learning, memory, and attentional processes. Salient neuropathological exemplars in a continuum of neurodegenerative conditions, such as the Alzheimer disease, are degenerative alterations in the basal forebrain cholinergic neurons, combined with reduced acetylcholine transmission [88]. Cholinergic receptor-targeting or acetylcholinesterase-inhibiting therapeutic interventions aim to increase the synaptic levels of acetylcholine and, consequently, reduce the cognitive impairment but they do not have a disease-modifying effect [89].

Dopaminergic modulation is one of the critical components of the therapeutic treatment of movement related neurodegenerative disorders, and especially Parkinson disease. Degeneration of the nigrostriatal dopaminergic neurons is linked to severe motor impairment and dysfunction of basal ganglia circuitry [90]. Both strategies to restore dopamine levels or to normalize dopamine receptor function has been proved to reduce motor impairments, and partially restore neural network integrity, thus supporting their continued applicability in the field of neuropharmacological therapies [91].

### 5.3 Serotonergic and Noradrenergic Targets

Serotonergic system coordinates affective states, cognition, sleep architecture, and neuroplasticity and

its malfunction is progressively reported in neurodegenerative pathologies. The neuropsychiatric phenotypes such as depressive syndromes, anxiety disorders and cognitive impairments are caused by aberrant signalling of serotonergic receptors and impaired serotonergic innervation. The pharmacologic stimulation of serotonergic receptors and transporters is a potential cure of non-motor clinical manifestation and, as a result, an increase in the quality of life of affected individuals [92]. It has been demonstrated that the noradrenergic system which is mostly derived in locus coeruleus is central in the regulation of attention, arousal, and neuroinflammatory events. Noradrenergic neuron degeneration aggravates cognitive impairments and predisposes an individual to neuroinflammation [93]. Therefore, noradrenergic receptor- and transport-based interventions can have therapeutic utility in stabilizing neuronal circuitry and curbing the effects of inflammation as well as enhancing neuroprotective mechanisms in relation to neurodegenerative disorders [94].

## **6. Neuroimmune and Inflammatory Targets**

### **6.1 Microglial and Astrocytic Modulation**

Microglial and astrocytic activity is another approach to neurodegenerative diseases, as the glial populations that microglia and astrocytes display play a fundamental role in neuroinflammation and neuronal homeostasis [95]. Activated microglia promotes disease progression through secretion of pro-inflammatory cytokines, reactive oxygen species and neurotoxic mediators, and astrocytes through the regulation of synaptic support, metabolic control and blood-brain barrier integrity [96]. The pharmacological approaches aimed at dampening the excitation of chronic glia, or promoting the adoption of anti-inflammatory phenotypes, have the potential to reduce neuronal damage, as well as to restore homeostatic cues [97]. This is because exploiting glia specific receptors, inflammatory processes and intracellular signalling pathways suggest the presence of disease modifying interventions which are more specific and less neurotoxic to the cells thus conforming to a mechanism based therapeutic paradigm [98].

### **6.2 Cytokines, Chemokines, and Complement Pathways**

The cytokines and chemokines as well as the complement pathways are the key mediators of neuroimmune crosstalk with essential roles in the etiology of neurodegenerative conditions. Chronic inflammation is perpetuated by aberrant cytokine signalling and is consequently followed by the induction of synaptic damage and relative neuronal degeneration [99]. The chemokines are also

important in controlling the recruitment of immune cells and glial activation in the central nervous system. Recurrent overexpression of chemokines enhances the migration of microglia and perpetuates inflammatory events affecting neurodegenerative pathways and disabling neuronal regeneration processes [100].

In physiological conditions the complement system plays a role in the pruning of synapses and immune surveillance but its binding in an aberrant manner increases the rate of synapse loss and neuronal damage. Targeted intervention of these mechanisms provides a therapeutic approach to the reduction of neuroinflammation and retention of key immune functions [101].

### **6.3 Immunomodulatory Pharmacological Strategies**

Immunomodulatory pharmacological approaches are meant to help regain immune homeostasis in neurodegenerative disorders by selective, specific intervention of inflammatory signalling pathways. These interventions include cytokine inhibitors, microglial-phenotype modulators and complement-cascade regulators in order to reduce chronic neuroinflammation [102]. Immunomodulatory agents can slow down the development of the disease and prevent neuronal damage by balancing the over activation of the immune system but not suppressing the necessary immune reactions that help in the protection of the body [103]. Such mechanisms-based interventions are disease-modifying potential and contribute to improved targeted therapies with improved efficacy and safety profiles in the sphere of neuropharmacological studies [104].

## **7. Novel Drug Modalities and Advanced Neuropharmacological Strategies**

The experimental drug modalities and developed neuropharmacological approaches are transforming the treatment paradigm of the neurodegenerative disorders by improving the specificity of targets and the delivery efficiency [105]. Gene therapy, RNA-based therapeutics, nanocarrier systems, and biologics are just some of the techniques that allow the accurate modulation of disease-relevant signalling cascades, thereby enhancing clinical outcome, and at the same time decreasing off-target effects and systemic toxicity [106].

### **7.1 Small-Molecule and Biologic Therapeutics**

Small-molecule therapeutics remain positioned centrally in terms of neuropharmacology, which is due to their exceptional oral absorption, ability to cross the blood brain barrier and their ability to regulate intracellular targets [107]. These agents are

widely used to regulate enzymatic activity, receptor interactions, ion channel dynamics that are linked to neurodegenerative diseases, to produce symptomatic benefits and, in some cases, have disease-modifying effects. Their selectivity and safety profiles have been further optimized by the application of the rational design principles and the high throughput screening technologies [108].

Monoclonal antibodies, peptides, and recombinant proteins have a high target specificity and long biological activity, which means they can serve as biologic therapeutics. Still, barriers to efficient delivery of the central nervous system persist, but new developments in the engineering of antibodies and development of delivery platforms have expanded the ability of these agents to specifically attack extracellular proteins, as well as neuroinflammatory mediators [109].

### 7.2 Gene- and RNA-Based Neurotherapies

Neurotherapies based on genes and RNAs represent the new approaches in reducing molecular imbalances underlying neurodegenerative diseases. Gene therapy methods use both viral and non-viral vectors as vectors to deliver functional genes or to regulate the expression of pathogenic genes, which will lead to the establishment of long-term therapeutic reactions [110]. The modalities endow the ability to correct genetic maladaptations and to control the expression of pathogenic pathways in their inception. One therapeutic approach, which involves RNA, is the control of target genes by antisense oligonucleotides, small interfering RNAs, messenger RNA platforms, and small interfering RNAs [111]. The recent advances in technologies of delivery and chemical modification methods have improved their stability, brain-targeting properties and safety profiles, strengthening their growing application in precision neuropharmacology [112].

### 7.3 Nanotechnology and Targeted Drug Delivery

Nanotechnology, alongside precision drug delivery architectures, has risen to a new hegemony in the context of the mitigation of the limitations that plague conventional neurotherapeutics, most notably the lack of permeability of therapeutics across the blood-brain barrier and the systemic toxicity that remains as a persistent consequence [113]. Within the given paradigm, Nano carriers, such as liposomes, polymeric nanoparticles, dendrimers, and solid lipid nanoparticles, provide control of drug delivery in actively being developed to slow the advancement of the disease. A more modern understanding of non-motor symptomatology and neuroinflammatory

time, increase pharmacokinetic stability, and improve cerebral targeting. These carriers can also be functionalized with certain ligands or monoclonal antibodies, further allowing specific translocation across the blood-brain barrier to neuronal or glial cell sub-compartments to improve the level of therapeutic specificity [114]. Also, these Nano platforms allow simultaneous delivery of several pharmacologic agonists, which allow synergistic regulation of pathogenic pathways, which interact. Collectively, the nanotechnology-based delivery platforms provide a strong and potentially radical direction of improving the efficacy and safety of neuropharmacological practice [115].

## 8. Disease-Specific Targeting Approaches

### 8.1 Alzheimer's Disease

Alzheimer is a progressive neurodegenerative disease with significant impairment of cognitive ability, synaptic degradation, and massive neuronal dysfunction [116]. Its neuropathology is characterized by extracellular deposition of amyloid  $\beta$  plaques, intracellular neurofibrillary tangles of hyperphosphorylated tau and chronic neuroinflammatory responses. The current treatment interventions mainly provide symptomatic treatment by regulating cholinergic deficiencies and blocking glutamatergic excitotoxicity [117]. However, the latest disease-modifying treatments are aimed at reducing amyloid and tau-pathology, controlling microglial activation, and strengthening synaptic functions. The future of disease management is being enabled by the recent advancements in biomarker-based diagnostics and precision pharmacology that provide the opportunity to intervene earlier and develop specific therapies that can slow down the disease progression [118].

### 8.2 Parkinson's Disease

Parkinson disease is a neurodegenerative movement disorder that is associated with the selective death of dopaminergic neurons in the substantia nigra and intracellular accumulation of alpha 2-synuclein [119]. Existing pharmacotherapeutic paradigms are still largely based on the paradigm of dopamine replacement, with levodopa and dopamine agonists being the main modalities that are used in curbing motor manifestation. New treatment opportunities are directed toward neuroprotection, mitochondrial abnormality, oxidative stress, and pathologic aggregation of  $\alpha$ -synuclein [120]. The investigation methods that include immunotherapies, gene-based interventions, and the precision delivery systems are pathways is increasingly defining the development of a more comprehensive and integrative treatment model [121].

### 8.3 Huntington's Disease

Huntington disease is a neurodegenerative condition that is caused by the expansion of CAG repeats in the huntingtin gene, which causes progressive motor, cognitive, and psychiatric impairments and is an inherited and neurodegenerative condition. Existing treatment methods are mostly symptomatic, and they aim at relieving the chorea and associated behavioural manifestations [122]. Disease-modifying interventions are becoming biased towards the inhibition of mutant huntingtin expression with antisense oligonucleotides, RNA interference and genome-editing technologies. Treating mitochondrial dysfunction, excitotoxicity and neuroinflammation is a promising area of treatment. Evidence of the most current developments in molecular genetics and precision neuropharmacology has significantly expanded the range of targeted intervention in this disorder [123].

### 8.4 Amyotrophic Lateral Sclerosis and Related Disorders

Amyotrophic lateral sclerosis (ALS) is characterized by selective hypergamy of upper- and lower-motor neurons, to the end that leads to progressive

muscular weakness and respiratory failure. Existing licensed pharmacotherapies have only a small benefit in survival, making a significant contribution via prevention of excitotoxicity and oxidative stress. Recent research focuses on immunomodulation, RNA-based therapies and gene-directed therapies as a measure to address sporadic and familial etiologies. The concepts of novel drug delivery systems and biomarker-based clinical strategies can improve the accuracy of therapy, and in the long term, the main goal is to slow the disease and increase the quality of life of people with ALS and similar motor neuron diseases [124].

Table 2 summarizes disease-specific molecular targets and emerging therapeutic strategies for major neurodegenerative disorders. It highlights key pathogenic targets, including amyloid- $\beta$ , tau,  $\alpha$ -synuclein, LRRK2, GBA, mutant huntingtin, and C9orf72, alongside corresponding therapeutic approaches and clinical development stages, emphasizing the transition toward precision medicine and targeted disease-modifying therapies [125].

**Table 2:** Disease-specific novel targets and emerging therapeutic strategies in neurodegenerative disorders.

| S. No. | Disorder             | Novel Target        | Target Type / Pathology                                | Therapeutic Strategy / Status              | References |
|--------|----------------------|---------------------|--------------------------------------------------------|--------------------------------------------|------------|
| 1.     | Alzheimer's Disease  | Amyloid- $\beta$    | Protein aggregation / Plaque formation                 | Monoclonal antibodies / Phase III          | [126]      |
| 2.     | Alzheimer's Disease  | Tau                 | Protein phosphorylation / Neurofibrillary tangles      | Immunotherapy / Small molecules / Phase II | [127]      |
| 3.     | Alzheimer's Disease  | BACE1               | Enzyme / A $\beta$ production                          | Small molecule inhibitors / Phase II/III   | [128]      |
| 4.     | Alzheimer's Disease  | APOE4               | Genetic variant / Lipid metabolism & amyloid clearance | Gene therapy / Small molecule / Phase I    | [129]      |
| 5.     | Parkinson's Disease  | $\alpha$ -Synuclein | Protein aggregation / Lewy body formation              | Immunotherapy / Phase I/II                 | [130]      |
| 6.     | Parkinson's Disease  | LRRK2               | Kinase / Mutation-driven neurodegeneration             | Small molecule inhibitors / Phase II       | [131]      |
| 7.     | Parkinson's Disease  | GBA                 | Enzyme / Lysosomal dysfunction                         | Small molecule chaperone / Phase II        | [132]      |
| 8.     | Huntington's Disease | Mutant huntingtin   | Protein / Toxic gain-of-function                       | ASO / RNAi / Phase III                     | [133]      |
| 9.     | Huntington's Disease | RNA toxicity        | RNA / Transcriptional dysregulation                    | ASO / RNAi / Phase II                      | [134]      |

|     |                      |                          |                                                |                                         |       |
|-----|----------------------|--------------------------|------------------------------------------------|-----------------------------------------|-------|
| 10. | Huntington's Disease | Epigenetic dysregulation | DNA / Histone / Transcriptional misregulation  | Small molecules / Phase I               | [135] |
| 11. | ALS                  | C9orf72                  | Genetic repeat / RNA foci & dipeptide toxicity | ASO / Gene silencing / Phase I/II       | [136] |
| 12. | ALS                  | Glutamate excitotoxicity | Neurotransmitter / Motor neuron death          | Receptor antagonists / Phase II         | [137] |
| 13. | FTD                  | Tau                      | Protein / Frontotemporal tangles               | Immunotherapy / Phase I/II              | [138] |
| 14. | FTD                  | C9orf72                  | Genetic repeat / RNA foci & dipeptide toxicity | ASO / Gene silencing / Phase I          | [139] |
| 15. | Alzheimer's Disease  | Synaptic dysfunction     | Synapse / Cognitive decline                    | Small molecules / Peptides / Phase I/II | [129] |


### 9. Translational and Clinical Perspectives

Neuropharmacology Translational and clinical approaches promote the need to connect mechanistic knowledge to therapeutic practice through the preclinical validation of rigour and clinically relevant outcomes [140]. The preclinical models, which include transgenic rodents, toxin induced paradigms, patient induced pluripotent stem cells and three dimensional organoid constructs, are essential in target validation, mechanistic dissection and pharmacodynamic studies [141]. With these systems, interrogation of disease-specific pathways, such as protein aggregation, mitochondrial dysfunction, neuroinflammation, and synaptic pathology, can be done, and dose optimization and safety profiling is also achieved. However, the nature of the constraints people may face in cross-functional predictions requires the implementation of multi-omics approaches and models of humans to enhance construct validity [142].

Biomarkers play a central role in clinical development, which provides early diagnostic ability, patient stratification, and therapeutic monitoring. Individually and in combination, fluid biomarkers (e.g., cerebrospinal fluid tau, amyloid-2, neurofilament light chain), neuroimaging (MRI, PET), and digitally derived variables obtained as a result of cognitive and motor testing have become objective disease progression and therapeutic response indicators. It is crucial that the proper clinical endpoints (i.e., cognitive scales and

functional tests) and composite progression indices should be used to prove the disease-modifying effects. In spite of these achievements, there are still issues facing clinical translation, which comprise, but are not limited to, patient-population heterogeneity, blood-brain barrier limitation, insufficient target engagement, late-stage intervention, and high attrition rates during clinical trials [143].

Figure 3 illustrates the translational pathway involved in the development of therapeutics for neurodegenerative diseases. The process begins with the identification and validation of promising molecular or cellular targets, followed by preclinical studies to evaluate pharmacological efficacy, mechanisms of action, pharmacokinetics, and safety. Successful candidates progress through phased clinical trials to assess tolerability, efficacy, dose optimization, and clinical outcomes in patient populations. Throughout this process, biomarker development and translational research support patient stratification, treatment monitoring, and evaluation of therapeutic responses. Regulatory evaluation subsequently assesses the quality, safety, and efficacy of the candidate before granting marketing authorization. Post-approval surveillance further evaluates long-term safety and real-world effectiveness. Collectively, this integrated pathway facilitates the systematic translation of promising discoveries into safe, effective, and clinically relevant disease-modifying therapies for neurodegenerative disorders [144].



**Figure 3:** Translational pipeline from target discovery to clinical application. Schematic representation of the drug development pipeline, illustrating the progression from target discovery and preclinical studies to clinical trials, regulatory review, and ultimately approved therapies.

### 10. Future Directions and Emerging Trends

The future trends of neuropharmacology focus more on accuracy and customization where genomic, transcriptomic, proteomic and biomarker information is combined to customize therapeutic interventions to specific disease patterns and progressions. Precision neuropharmacology aims to categorize patients using molecular signatures and, therefore, providing specific interventions that would increase therapeutic efficacy and reduce adverse effects. Simultaneously, developments in machine learning and artificial intelligence (AI) are reshaping the target discovery and drug design process by accelerating novel molecular target discovery, drug-target interactions, lead compound optimization and re-using the pharmacotherapies available in the clinic through large-scale data analytics and in silico models. Furthermore, due to the multifactorial etiology of neurodegenerative diseases, new concepts predict multi-target and combination therapies, which simultaneously change interconnected pathological processes, including: protein aggregation, neuroinflammation, oxidative stress, and mitochondrial dysfunction. The combination of such integrative, technology-driven methods has the potential to develop disease modifying therapies and the next-generation neurotherapeutics.

### Conclusion

Neurodegenerative diseases are chronic diseases that involve loss of neurons, dysfunction of synapses and a multifactorial process that goes beyond the

conventional neurotransmitter depletion. The existing treatment options mainly provide symptomatic treatment without slowing down disease advancement, which is why the implementation of disease-modifying interventions is urgently needed. The recent developments in the field of molecular biology have provided major pathogenic pathways, such as protein misfolding, dysfunction of the mitochondria, oxidative stress, neuroinflammation, impaired proteostasis, and synaptic degeneration. These findings have given neuropharmacology a new path of multi-target, mechanism-based therapeutic techniques. Newer targets like kinases, epigenetic regulators, neuroimmune mediators and autophagy pathways offer good prospects of intervention. At the same time, translational potential is being broadened by biologics, RNA-based, and gene-based approaches, and drug delivery systems based on nanotechnology. Precision medicine strategies are also enhanced by the use of biomarkers to stratify. However, such issues as target validation, clinical heterogeneity, and blood-brain barrier permeability are also major issues. A coordinated, individualized and translational model must be applied in the realization of effective neuroprotection and enhancement of long-term clinical outcomes.

### Acknowledgements

The authors sincerely acknowledge Minerva College of Pharmacy, Indora, Himachal Pradesh, India, for providing the facilities and academic support for the

preparation of this review. The authors also thank the scientific community for their valuable contributions to neuropharmacology and neurodegenerative disease research.

### Author Contributions

**SQ:** Conceptualization and Writing-original draft; **N:** Supervision and Writing-review & editing.

### Funding

No external funding was received for this work.

### Conflict of Interest

The authors declare no conflict of interest regarding the publication of this manuscript.

### References

1. G. Tesco and S. Lomoio, "Pathophysiology of neurodegenerative diseases: An interplay among axonal transport failure, oxidative stress, and inflammation?," (in eng), *Semin Immunol*, vol. 59, p. 101628, Jan 2022, doi: 10.1016/j.smim.2022.101628.
2. J. Y. Xi *et al.*, "Effects of population aging on quality of life and disease burden: a population-based study," (in eng), *Glob Health Res Policy*, vol. 10, no. 1, p. 2, Jan 14 2025, doi: 10.1186/s41256-024-00393-8.
3. H. Alfalahi, S. B. Dias, A. H. Khandoker, K. R. Chaudhuri, and L. J. Hadjileontiadis, "A scoping review of neurodegenerative manifestations in explainable digital phenotyping," (in eng), *NPJ Parkinsons Dis*, vol. 9, no. 1, p. 49, Mar 30 2023, doi: 10.1038/s41531-023-00494-0.
4. S. Wang, Y. Jiang, A. Yang, F. Meng, and J. Zhang, "The Expanding Burden of Neurodegenerative Diseases: An Unmet Medical and Social Need," (in eng), *Aging Dis*, vol. 16, no. 5, pp. 2937-2952, Nov 4 2024, doi: 10.14336/ad.2024.1071.
5. S. Kumar, D. Tomar, D. Kumar, and V. Kishore, "Applications of polymeric nanoparticle in nose to brain drug delivery," *Research Journal of Pharmacy and Technology*, vol. 16, no. 12, pp. 6087-6094, 2023.
6. T. Fan, J. Peng, H. Liang, W. Chen, J. Wang, and R. Xu, "Potential common pathogenesis of several neurodegenerative diseases," (in eng), *Neural Regen Res*, vol. 21, no. 3, pp. 972-988, Mar 1 2026, doi: 10.4103/nrr.Nrr-d-24-01054.
7. H. Xing *et al.*, "Recent Advances in Drug Development for Alzheimer's Disease: A Comprehensive Review," (in eng), *Int J Mol Sci*, vol. 26, no. 8, Apr 21 2025, doi: 10.3390/ijms26083905.
8. M. M. Lalu *et al.*, "Identifying and understanding factors that affect the translation of therapies from the laboratory to patients: a study protocol," (in eng), *F1000Res*, vol. 9, p. 485, 2020, doi: 10.12688/f1000research.23663.2.
9. L. Wang *et al.*, "Future embracing: exosomes driving a revolutionary approach to the diagnosis and treatment of idiopathic membranous nephropathy," (in eng), *J Nanobiotechnology*, vol. 22, no. 1, p. 472, Aug 8 2024, doi: 10.1186/s12951-024-02633-y.
10. D. Kumar, G. Md Ashraf, A. L. Bilgrami, and M. Imtaiyaz Hassan, "Emerging therapeutic developments in neurodegenerative diseases: A clinical investigation," (in eng), *Drug Discov Today*, vol. 27, no. 10, p. 103305, Oct 2022, doi: 10.1016/j.drudis.2022.06.005.
11. Q. Cai and D. Ganesan, "Regulation of neuronal autophagy and the implications in neurodegenerative diseases," (in eng), *Neurobiol Dis*, vol. 162, p. 105582, Jan 2022, doi: 10.1016/j.nbd.2021.105582.
12. M. Carrier, K. Dolhan, B. C. Bobotis, M. Desjardins, and M. Tremblay, "The implication of a diversity of non-neuronal cells in disorders affecting brain networks," (in eng), *Front Cell Neurosci*, vol. 16, p. 1015556, 2022, doi: 10.3389/fncel.2022.1015556.
13. J. Montaner *et al.*, "Multilevel omics for the discovery of biomarkers and therapeutic targets for stroke," (in eng), *Nat Rev Neurol*, vol. 16, no. 5, pp. 247-264, May 2020, doi: 10.1038/s41582-020-0350-6.
14. Q. Huang, L. Chen, J. Liang, Q. Huang, and H. Sun, "Neurotransmitters: Potential Targets in Glioblastoma," (in eng), *Cancers (Basel)*, vol. 14, no. 16, Aug 17 2022, doi: 10.3390/cancers14163970.
15. N. Treder and T. Bączek, "Sialic Acid in Neurodegenerative and Psychiatric Disorders:

### Ethics approval and consent to participate

Not applicable

### AI Declaration

The authors declare that they did not use artificial intelligence (AI) tools to generate or draft the scientific content of this manuscript. ChatGPT and Grammarly AI were used solely to improve the language, grammar, readability, and clarity of the manuscript. All AI-assisted suggestions were carefully reviewed, verified, and edited by the authors, who take full responsibility for the accuracy, originality, and integrity of the final content.

- From Molecular Regulation to Targeted Nanocarrier-Based Therapy," (in eng), *Pharmaceutics*, vol. 17, no. 12, Dec 10 2025, doi: 10.3390/pharmaceutics17121593.
16. S. Kumar, D. Kumar, S. Gulia, and M. Thakur, "Traumatic brain injury: Role in induction and progression of neurodegenerative disorders," *Research Journal of Pharmacy and Technology*, vol. 17, no. 4, pp. 1909-1915, 2024.
  17. G. E. Aranda-Abreu, F. Rojas-Durán, M. E. Hernández-Aguilar, D. Herrera-Covarrubias, L. R. Tlapa-Monge, and S. L. Mestizo-Gutiérrez, "The Molecular Architecture of Neurodegeneration: An Integrative Overview of Convergent Mechanisms," (in eng), *NeuroSci*, vol. 7, no. 1, Jan 6 2026, doi: 10.3390/neurosci7010007.
  18. S. Masoli, M. F. Rizza, M. Tognolina, F. Prestori, and E. D'Angelo, "Computational models of neurotransmission at cerebellar synapses unveil the impact on network computation," (in eng), *Front Comput Neurosci*, vol. 16, p. 1006989, 2022, doi: 10.3389/fncom.2022.1006989.
  19. R. I. Teleanu, A. G. Niculescu, E. Roza, O. Vladăcenco, A. M. Grumezescu, and D. M. Teleanu, "Neurotransmitters-Key Factors in Neurological and Neurodegenerative Disorders of the Central Nervous System," (in eng), *Int J Mol Sci*, vol. 23, no. 11, May 25 2022, doi: 10.3390/ijms23115954.
  20. B. Alharbi *et al.*, "Role of GABA pathway in motor and non-motor symptoms in Parkinson's disease: a bidirectional circuit," (in eng), *Eur J Med Res*, vol. 29, no. 1, p. 205, Mar 27 2024, doi: 10.1186/s40001-024-01779-7.
  21. A. de Bartolomeis, L. Vellucci, G. De Simone, B. Mazza, A. Barone, and M. Ciccarelli, "Dysregulated Signaling at Postsynaptic Density: A Systematic Review and Translational Appraisal for the Pathophysiology, Clinics, and Antipsychotics' Treatment of Schizophrenia," (in eng), *Cells*, vol. 12, no. 4, Feb 10 2023, doi: 10.3390/cells12040574.
  22. W. L. Wu, X. X. Gong, Z. H. Qin, and Y. Wang, "Molecular mechanisms of excitotoxicity and their relevance to the pathogenesis of neurodegenerative diseases-an update," (in eng), *Acta Pharmacol Sin*, vol. 46, no. 12, pp. 3129-3142, Dec 2025, doi: 10.1038/s41401-025-01576-w.
  23. J. J. Lochhead, J. Yang, P. T. Ronaldson, and T. P. Davis, "Structure, Function, and Regulation of the Blood-Brain Barrier Tight Junction in Central Nervous System Disorders," (in eng), *Front Physiol*, vol. 11, p. 914, 2020, doi: 10.3389/fphys.2020.00914.
  24. H. Fong *et al.*, "Recapitulation of Structure-Function-Regulation of Blood-Brain Barrier under (Patho)Physiological Conditions," (in eng), *Cells*, vol. 13, no. 3, Jan 30 2024, doi: 10.3390/cells13030260.
  25. A. Achar, R. Myers, and C. Ghosh, "Drug Delivery Challenges in Brain Disorders across the Blood-Brain Barrier: Novel Methods and Future Considerations for Improved Therapy," (in eng), *Biomedicines*, vol. 9, no. 12, Dec 4 2021, doi: 10.3390/biomedicines9121834.
  26. S. B. Kondaveeti *et al.*, "Next-generation microneedle platforms for site-specific management of diabetic neuropathy," *Diabetology & Metabolic Syndrome*, vol. 17, no. 1, p. 418, 2025/11/06 2025, doi: 10.1186/s13098-025-01966-4.
  27. H. M. Yang, "Overcoming the Blood-Brain Barrier: Advanced Strategies in Targeted Drug Delivery for Neurodegenerative Diseases," (in eng), *Pharmaceutics*, vol. 17, no. 8, Aug 11 2025, doi: 10.3390/pharmaceutics17081041.
  28. M. C. Jurcău *et al.*, "The Link between Oxidative Stress, Mitochondrial Dysfunction and Neuroinflammation in the Pathophysiology of Alzheimer's Disease: Therapeutic Implications and Future Perspectives," (in eng), *Antioxidants (Basel)*, vol. 11, no. 11, Oct 31 2022, doi: 10.3390/antiox11112167.
  29. P. Bloomingdale *et al.*, "Hallmarks of neurodegenerative disease: A systems pharmacology perspective," (in eng), *CPT Pharmacometrics Syst Pharmacol*, vol. 11, no. 11, pp. 1399-1429, Nov 2022, doi: 10.1002/psp4.12852.
  30. A. El Elhaj and M. E. Onger, "Exploring Neurodegenerative Diseases: Bridging the Gap between in vitro and in vivo Models," (in eng), *Curr Pharm Des*, Jun 24 2025, doi: 10.2174/0113816128374254250605070049.
  31. Z. Tanoli, A. Schulman, and T. Aittokallio, "Validation guidelines for drug-target prediction methods," (in eng), *Expert Opin Drug Discov*, vol. 20, no. 1, pp. 31-45, Jan 2025, doi: 10.1080/17460441.2024.2430955.
  32. Y. Zheng *et al.*, "A deep generative model for deciphering cellular dynamics and in silico drug discovery in complex diseases," (in eng), *Nat Biomed Eng*, vol. 9, no. 12, pp. 2155-2180, Dec 2025, doi: 10.1038/s41551-025-01423-7.
  33. D. Kumar and R. Tanwar, "Nanoscience and the Future: Transforming Technologies for Sustainable Development," *Current Engineering Letters and Reviews*, vol. 2, no. 1,

- 2025, doi: <https://doi.org/10.2174/012666948X386929250411055923>.
34. O. Koszła and P. Solek, "Misfolding and aggregation in neurodegenerative diseases: protein quality control machinery as potential therapeutic clearance pathways," (in eng), *Cell Commun Signal*, vol. 22, no. 1, p. 421, Aug 30 2024, doi: 10.1186/s12964-024-01791-8.
  35. N. Brezic, S. Gligorevic, A. Sic, and N. N. Knezevic, "Protein Misfolding and Aggregation as a Mechanistic Link Between Chronic Pain and Neurodegenerative Diseases," (in eng), *Curr Issues Mol Biol*, vol. 47, no. 4, Apr 8 2025, doi: 10.3390/cimb47040259.
  36. Q. Jiang *et al.*, "Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances," (in eng), *Signal Transduct Target Ther*, vol. 10, no. 1, p. 76, Mar 10 2025, doi: 10.1038/s41392-025-02145-7.
  37. M. Sidoryk-Węgrzynowicz, K. Adamiak, and L. Strużyńska, "Targeting Protein Misfolding and Aggregation as a Therapeutic Perspective in Neurodegenerative Disorders," (in eng), *Int J Mol Sci*, vol. 25, no. 22, Nov 20 2024, doi: 10.3390/ijms252212448.
  38. J. Qu, T. Zou, and Z. Lin, "The Roles of the Ubiquitin-Proteasome System in the Endoplasmic Reticulum Stress Pathway," (in eng), *Int J Mol Sci*, vol. 22, no. 4, Feb 3 2021, doi: 10.3390/ijms22041526.
  39. W. Li, H. L. Li, J. Z. Wang, R. Liu, and X. Wang, "Abnormal protein post-translational modifications induces aggregation and abnormal deposition of protein, mediating neurodegenerative diseases," (in eng), *Cell Biosci*, vol. 14, no. 1, p. 22, Feb 12 2024, doi: 10.1186/s13578-023-01189-y.
  40. B. Chauhan *et al.*, "Precision breast oncology: molecular insights and transformative clinical strategies," *Cancer Treatment and Research Communications*, vol. 47, p. 101242, 2026/01/01/ 2026, doi: <https://doi.org/10.1016/j.ctarc.2026.101242>.
  41. C. Hu, M. Lin, C. Wang, and S. Zhang, "Current Understanding of Protein Aggregation in Neurodegenerative Diseases," (in eng), *Int J Mol Sci*, vol. 26, no. 21, Oct 30 2025, doi: 10.3390/ijms262110568.
  42. E. Pongrácová, E. Buratti, and M. Romano, "Prion-like Spreading of Disease in TDP-43 Proteinopathies," (in eng), *Brain Sci*, vol. 14, no. 11, Nov 9 2024, doi: 10.3390/brainsci14111132.
  43. G. Plascencia-Villa and G. Perry, "Roles of Oxidative Stress in Synaptic Dysfunction and Neuronal Cell Death in Alzheimer's Disease," (in eng), *Antioxidants (Basel)*, vol. 12, no. 8, Aug 17 2023, doi: 10.3390/antiox12081628.
  44. U. C. Dash *et al.*, "Oxidative stress and inflammation in the pathogenesis of neurological disorders: Mechanisms and implications," (in eng), *Acta Pharm Sin B*, vol. 15, no. 1, pp. 15-34, Jan 2025, doi: 10.1016/j.apsb.2024.10.004.
  45. K. A. Cojocaru *et al.*, "Mitochondrial Dysfunction, Oxidative Stress, and Therapeutic Strategies in Diabetes, Obesity, and Cardiovascular Disease," (in eng), *Antioxidants (Basel)*, vol. 12, no. 3, Mar 7 2023, doi: 10.3390/antiox12030658.
  46. D. Steffan, C. Pezzini, M. Esposito, and A. Franco-Romero, "Mitochondrial Aging in the CNS: Unravelling Implications for Neurological Health and Disease," (in eng), *Biomolecules*, vol. 15, no. 9, Aug 29 2025, doi: 10.3390/biom15091252.
  47. A. Adamu, S. Li, F. Gao, and G. Xue, "The role of neuroinflammation in neurodegenerative diseases: current understanding and future therapeutic targets," (in eng), *Front Aging Neurosci*, vol. 16, p. 1347987, 2024, doi: 10.3389/fnagi.2024.1347987.
  48. J. Qin, Z. Ma, X. Chen, and S. Shu, "Microglia activation in central nervous system disorders: A review of recent mechanistic investigations and development efforts," (in eng), *Front Neurol*, vol. 14, p. 1103416, 2023, doi: 10.3389/fneur.2023.1103416.
  49. J. C. Patel, M. Shukla, and M. Shukla, "Cellular and Molecular Interactions in CNS Injury: The Role of Immune Cells and Inflammatory Responses in Damage and Repair," (in eng), *Cells*, vol. 14, no. 12, Jun 18 2025, doi: 10.3390/cells14120918.
  50. R. Dass *et al.*, "Optimization and Evaluation of Itopride Hydrochloride-Loaded Eudragit S100/Ethylcellulose Gastroretentive Electrospun Nanofibers for the Treatment of Gastroesophageal Reflux Disease," *Journal of Pharmaceutical Innovation*, vol. 20, no. 6, p. 225, 2025/10/17 2025, doi: 10.1007/s12247-025-10135-z.
  51. M. García-Domínguez, "Glial Cell Dynamics in Neuroinflammation: Mechanisms, Interactions, and Therapeutic Implications," (in eng), *Biomedicines*, vol. 14, no. 1, Jan 6 2026, doi: 10.3390/biomedicines14010115.
  52. Y. Ratan *et al.*, "An Insight into Cellular and Molecular Mechanisms Underlying the Pathogenesis of Neurodegeneration in Alzheimer's Disease," (in eng), *Biomedicines*,

- vol. 11, no. 5, May 8 2023, doi: 10.3390/biomedicines11051398.
53. M. Sciacaluga *et al.*, "An Unbalanced Synaptic Transmission: Cause or Consequence of the Amyloid Oligomers Neurotoxicity?," (in eng), *Int J Mol Sci*, vol. 22, no. 11, Jun 1 2021, doi: 10.3390/ijms22115991.
  54. J. W. Błaszczyk, "Energy Metabolism Decline in the Aging Brain-Pathogenesis of Neurodegenerative Disorders," (in eng), *Metabolites*, vol. 10, no. 11, Nov 7 2020, doi: 10.3390/metabo10110450.
  55. B. J. Andreone, M. Larhammar, and J. W. Lewcock, "Cell Death and Neurodegeneration," (in eng), *Cold Spring Harb Perspect Biol*, vol. 12, no. 2, Feb 3 2020, doi: 10.1101/cshperspect.a036434.
  56. C. M. Curieses Andrés, J. M. Pérez de la Lastra, C. Andrés Juan, F. J. Plou, and E. Pérez-Lebeña, "From reactive species to disease development: Effect of oxidants and antioxidants on the cellular biomarkers," (in eng), *J Biochem Mol Toxicol*, vol. 37, no. 11, p. e23455, Nov 2023, doi: 10.1002/jbt.23455.
  57. J. Woo *et al.*, "Power Failure of Mitochondria and Oxidative Stress in Neurodegeneration and Its Computational Models," (in eng), *Antioxidants (Basel)*, vol. 10, no. 2, Feb 3 2021, doi: 10.3390/antiox10020229.
  58. M. Zayed, Y. C. Kim, and B. H. Jeong, "Biological characteristics and transcriptomic profile of adipose-derived mesenchymal stem cells isolated from prion-infected murine model," (in eng), *Stem Cell Res Ther*, vol. 16, no. 1, p. 154, Mar 28 2025, doi: 10.1186/s13287-025-04273-x.
  59. J. X. Song, J. Liu, Y. Jiang, Z. Y. Wang, and M. Li, "Transcription factor EB: an emerging drug target for neurodegenerative disorders," (in eng), *Drug Discov Today*, vol. 26, no. 1, pp. 164-172, Jan 2021, doi: 10.1016/j.drudis.2020.10.013.
  60. F. Provenzano, C. Torazza, T. Bonifacino, G. Bonanno, and M. Milanese, "The Key Role of Astrocytes in Amyotrophic Lateral Sclerosis and Their Commitment to Glutamate Excitotoxicity," (in eng), *Int J Mol Sci*, vol. 24, no. 20, Oct 21 2023, doi: 10.3390/ijms242015430.
  61. Q. Y. Wu *et al.*, "Syntaphilin mediates axonal growth and synaptic changes through regulation of mitochondrial transport: a potential pharmacological target for neurodegenerative diseases," (in eng), *J Drug Target*, vol. 31, no. 7, pp. 685-692, Aug 2023, doi: 10.1080/1061186x.2023.2230522.
  62. J. Wang, W. W. Hu, Z. Jiang, and M. J. Feng, "Advances in treatment of neurodegenerative diseases: Perspectives for combination of stem cells with neurotrophic factors," (in eng), *World J Stem Cells*, vol. 12, no. 5, pp. 323-338, May 26 2020, doi: 10.4252/wjsc.v12.i5.323.
  63. Y. Zhao, M. Lin, F. Zhai, J. Chen, and X. Jin, "Exploring the Role of Ubiquitin-Proteasome System in the Pathogenesis of Parkinson's Disease," (in eng), *Pharmaceuticals (Basel)*, vol. 17, no. 6, Jun 14 2024, doi: 10.3390/ph17060782.
  64. M. Sharbafshaaer *et al.*, "Neuroaxonal Degeneration as a Converging Mechanism in Motor Neuron Diseases (MNDs): Molecular Insights into RNA Dysregulation and Emerging Therapeutic Targets," (in eng), *Int J Mol Sci*, vol. 26, no. 15, Aug 7 2025, doi: 10.3390/ijms26157644.
  65. L. M. De Plano, A. Saitta, S. Oddo, and A. Caccamo, "Epigenetic Changes in Alzheimer's Disease: DNA Methylation and Histone Modification," (in eng), *Cells*, vol. 13, no. 8, Apr 21 2024, doi: 10.3390/cells13080719.
  66. A. Sędzikowska and L. Szablewski, "Insulin and Insulin Resistance in Alzheimer's Disease," (in eng), *Int J Mol Sci*, vol. 22, no. 18, Sep 15 2021, doi: 10.3390/ijms22189987.
  67. A. A. Farooqui and T. Farooqui, "Phospholipids, Sphingolipids, and Cholesterol-Derived Lipid Mediators and Their Role in Neurological Disorders," (in eng), *Int J Mol Sci*, vol. 25, no. 19, Oct 3 2024, doi: 10.3390/ijms251910672.
  68. C. Hu, Y. Yan, Y. Jin, J. Yang, Y. Xi, and Z. Zhong, "Decoding the Cellular Trafficking of Prion-like Proteins in Neurodegenerative Diseases," (in eng), *Neurosci Bull*, vol. 40, no. 2, pp. 241-254, Feb 2024, doi: 10.1007/s12264-023-01115-9.
  69. Y. Yang, H. Chen, Q. Liu, Y. Niu, C. Mao, and R. Wang, "Elucidating molecular pathogenesis and developing targeted therapeutic interventions for cerebrovascular endothelial cell-mediated vascular dementia," (in eng), *Front Aging Neurosci*, vol. 17, p. 1623050, 2025, doi: 10.3389/fnagi.2025.1623050.
  70. S. N. Rahmatkar and D. Singh, "Decoding the Role of Neurotrophins in Glycogen Synthase Kinase 3-Beta Regulation in Alzheimer's Disease," (in eng), *Mol Neurobiol*, vol. 62, no. 7, pp. 8603-8623, Jul 2025, doi: 10.1007/s12035-025-04776-x.
  71. X. Wu *et al.*, "Protein kinases in neurodegenerative diseases: current understandings and implications for drug discovery," (in eng), *Signal Transduct Target*

- Ther*, vol. 10, no. 1, p. 146, May 7 2025, doi: 10.1038/s41392-025-02179-x.
72. H. Wei *et al.*, "Direct Activation of Protein Phosphatase 2A (PP2A) by Tricyclic Sulfonamides Ameliorates Alzheimer's Disease Pathogenesis in Cell and Animal Models," (in eng), *Neurotherapeutics*, vol. 17, no. 3, pp. 1087-1103, Jul 2020, doi: 10.1007/s13311-020-00841-6.
  73. T. Wu, W. Cai, and X. Chen, "Epigenetic regulation of neurotransmitter signaling in neurological disorders," (in eng), *Neurobiol Dis*, vol. 184, p. 106232, Aug 2023, doi: 10.1016/j.nbd.2023.106232.
  74. M. G. Gladkova, E. Leidmaa, and E. A. Anderzhanova, "Epidrugs in the Therapy of Central Nervous System Disorders: A Way to Drive on?," (in eng), *Cells*, vol. 12, no. 11, May 24 2023, doi: 10.3390/cells12111464.
  75. P. S. M. Pinheiro, L. P. Diniz, L. S. Franco, M. Siqueira, and F. C. A. Gomes, "Histone Deacetylases in Neurodegenerative Diseases and Their Potential Role as Therapeutic Targets: Shedding Light on Astrocytes," (in eng), *Pharmaceuticals (Basel)*, vol. 18, no. 10, Sep 30 2025, doi: 10.3390/ph18101471.
  76. A. Usmani, M. A. Siddiqui, D. Kumar, S. Gowri, T. J. Webster, and M. Faiyazuddin, "Next 5 years in autoimmunity: predictive diagnostics, immune signatures, and personalized immune therapy," *International Immunopharmacology*, vol. 179, p. 116530, 2026/06/15/ 2026, doi: <https://doi.org/10.1016/j.intimp.2026.116530>.
  77. S. Finkbeiner, "The Autophagy Lysosomal Pathway and Neurodegeneration," (in eng), *Cold Spring Harb Perspect Biol*, vol. 12, no. 3, Mar 2 2020, doi: 10.1101/cshperspect.a033993.
  78. W. Li *et al.*, "Selective autophagy of intracellular organelles: recent research advances," (in eng), *Theranostics*, vol. 11, no. 1, pp. 222-256, 2021, doi: 10.7150/thno.49860.
  79. S. Panwar *et al.*, "Role of autophagy and proteostasis in neurodegenerative diseases: Exploring the therapeutic interventions," (in eng), *Chem Biol Drug Des*, vol. 103, no. 4, p. e14515, Apr 2024, doi: 10.1111/cbdd.14515.
  80. T. Numakawa and R. Kajihara, "Involvement of brain-derived neurotrophic factor signaling in the pathogenesis of stress-related brain diseases," (in eng), *Front Mol Neurosci*, vol. 16, p. 1247422, 2023, doi: 10.3389/fnmol.2023.1247422.
  81. S. B. Kondaveeti *et al.*, "Repurposing Imeglimin for Chemotherapy-Induced Cognitive Impairment: Targeting Mitochondrial Dysfunction and Neuroinflammation," *Cellular and Molecular Neurobiology*, vol. 46, no. 1, p. 51, 2026/02/10 2026, doi: 10.1007/s10571-026-01684-z.
  82. A. A. Singh, S. Katiyar, and M. Song, "Phytochemicals Targeting BDNF Signaling for Treating Neurological Disorders," (in eng), *Brain Sci*, vol. 15, no. 3, Feb 27 2025, doi: 10.3390/brainsci15030252.
  83. T. Numakawa and R. Kajihara, "The Role of Brain-Derived Neurotrophic Factor as an Essential Mediator in Neuronal Functions and the Therapeutic Potential of Its Mimetics for Neuroprotection in Neurologic and Psychiatric Disorders," (in eng), *Molecules*, vol. 30, no. 4, Feb 12 2025, doi: 10.3390/molecules30040848.
  84. A. Panossian, T. Lemerond, and T. Efferth, "Adaptogens in Long-Lasting Brain Fatigue: An Insight from Systems Biology and Network Pharmacology," (in eng), *Pharmaceuticals (Basel)*, vol. 18, no. 2, Feb 15 2025, doi: 10.3390/ph18020261.
  85. N. Puranik and M. Song, "Glutamate: Molecular Mechanisms and Signaling Pathway in Alzheimer's Disease, a Potential Therapeutic Target," (in eng), *Molecules*, vol. 29, no. 23, Dec 5 2024, doi: 10.3390/molecules29235744.
  86. G. Juvenal *et al.*, "Regulation of GABAergic neurotransmission by purinergic receptors in brain physiology and disease," (in eng), *Purinergic Signal*, vol. 21, no. 1, pp. 149-177, Feb 2025, doi: 10.1007/s11302-024-10034-x.
  87. Z. Yang, Y. Zou, and L. Wang, "Neurotransmitters in Prevention and Treatment of Alzheimer's Disease," (in eng), *Int J Mol Sci*, vol. 24, no. 4, Feb 14 2023, doi: 10.3390/ijms24043841.
  88. Z. R. Chen, J. B. Huang, S. L. Yang, and F. F. Hong, "Role of Cholinergic Signaling in Alzheimer's Disease," (in eng), *Molecules*, vol. 27, no. 6, Mar 10 2022, doi: 10.3390/molecules27061816.
  89. M. P. Moreta, N. Burgos-Alonso, M. Torrecilla, J. Marco-Contelles, and C. Bruzos-Cidón, "Efficacy of Acetylcholinesterase Inhibitors on Cognitive Function in Alzheimer's Disease. Review of Reviews," (in eng), *Biomedicines*, vol. 9, no. 11, Nov 15 2021, doi: 10.3390/biomedicines9111689.
  90. S. Ramesh and A. Arachchige, "Depletion of dopamine in Parkinson's disease and relevant therapeutic options: A review of the literature," (in eng), *AIMS Neurosci*, vol. 10, no. 3, pp. 200-231, 2023, doi: 10.3934/Neuroscience.2023017.

91. C. Wu *et al.*, "Normalization effect of dopamine replacement therapy on brain functional connectome in Parkinson's disease," (in eng), *Hum Brain Mapp*, vol. 44, no. 9, pp. 3845-3858, Jun 15 2023, doi: 10.1002/hbm.26316.
92. L. P. Dolgacheva, V. P. Zinchenko, A. D. Nadeev, and N. V. Goncharov, "Serotonergic Regulation in Alzheimer's Disease," (in eng), *Int J Mol Sci*, vol. 26, no. 11, May 29 2025, doi: 10.3390/ijms26115218.
93. A. Galgani, M. Scotto, U. Faraguna, and F. S. Giorgi, "Fading Blue: Exploring the Causes of Locus Coeruleus Damage Across the Lifespan," (in eng), *Antioxidants (Basel)*, vol. 14, no. 3, Feb 22 2025, doi: 10.3390/antiox14030255.
94. R. Durcan, C. O'Callaghan, and J. B. Rowe, "Noradrenergic therapies in neurodegenerative disease: from symptomatic to disease modifying therapy?," (in eng), *Brain Commun*, vol. 7, no. 5, p. fcaf310, 2025, doi: 10.1093/braincomms/fcaf310.
95. Q. Deng, C. Wu, E. Parker, T. C. Liu, R. Duan, and L. Yang, "Microglia and Astrocytes in Alzheimer's Disease: Significance and Summary of Recent Advances," (in eng), *Aging Dis*, vol. 15, no. 4, pp. 1537-1564, Aug 1 2024, doi: 10.14336/ad.2023.0907.
96. T. Ponce-Lopez, "Peripheral Inflammation and Insulin Resistance: Their Impact on Blood-Brain Barrier Integrity and Glia Activation in Alzheimer's Disease," (in eng), *Int J Mol Sci*, vol. 26, no. 9, Apr 29 2025, doi: 10.3390/ijms26094209.
97. S. Babu Kondaveeti *et al.*, "Crocin as a Neuroprotective Agent: Targeting Western Diet-Induced Cognitive Dysfunction Through Antioxidant, Anti-Inflammatory and Gut-Brain Axis Modulation," *ASN Neuro*, vol. 18, no. 1, p. 2603409, 2025/12/19 2026, doi: 10.1080/17590914.2025.2603409.
98. A. McKenzie, R. Dombrower, N. Theeraphappong, S. McKenzie, and M. A. Hijazin, "Glial Activation, Neuroinflammation, and Loss of Neuroprotection in Chronic Pain: Cellular Mechanisms and Emerging Therapeutic Strategies," (in eng), *Biomedicines*, vol. 14, no. 1, Dec 26 2025, doi: 10.3390/biomedicines14010058.
99. A. Rauf *et al.*, "Neuroinflammatory Markers: Key Indicators in the Pathology of Neurodegenerative Diseases," (in eng), *Molecules*, vol. 27, no. 10, May 17 2022, doi: 10.3390/molecules27103194.
100. E. Ahremenko, A. Andreev, D. Apushkin, and E. Korkotian, "Glial Cells in the Early Stages of Neurodegeneration: Pathogenesis and Therapeutic Targets," (in eng), *Int J Mol Sci*, vol. 26, no. 24, Dec 12 2025, doi: 10.3390/ijms262411995.
101. H. Liu *et al.*, "The Role of the Complement System in Synaptic Pruning after Stroke," (in eng), *Aging Dis*, vol. 16, no. 3, pp. 1452-1470, Jun 25 2024, doi: 10.14336/ad.2024.0373.
102. J. Rudnicka-Czerwicz and H. Bartosik-Psujek, "Innate Immunity in the Pathogenesis of Selected Autoimmune Neurological Diseases," (in eng), *J Clin Med*, vol. 14, no. 20, Oct 14 2025, doi: 10.3390/jcm14207235.
103. S. Singh *et al.*, "Next generation preventive neurology: how artificial intelligence and machine learning are reshaping Alzheimer's disease research," *Behavioral and Brain Functions*, vol. 22, no. 1, p. 21, 2026/03/31 2026, doi: 10.1186/s12993-026-00329-x.
104. A. Krsek, L. Ostojic, D. Zivalj, and L. Baticic, "Navigating the Neuroimmunomodulation Frontier: Pioneering Approaches and Promising Horizons-A Comprehensive Review," (in eng), *Int J Mol Sci*, vol. 25, no. 17, Sep 7 2024, doi: 10.3390/ijms25179695.
105. R. N. L. Lamptey, B. Chaulagain, R. Trivedi, A. Gothwal, B. Layek, and J. Singh, "A Review of the Common Neurodegenerative Disorders: Current Therapeutic Approaches and the Potential Role of Nanotherapeutics," (in eng), *Int J Mol Sci*, vol. 23, no. 3, Feb 6 2022, doi: 10.3390/ijms23031851.
106. T. Ren, L. Ma, P. Fu, and C. Zhang, "Nanoparticles Used for the Delivery of RNAi-Based Therapeutics," (in eng), *Pharmaceutics*, vol. 17, no. 11, Nov 20 2025, doi: 10.3390/pharmaceutics17111502.
107. P. Yadav, S. Kumar, and D. Kumar, "Smart Drug Delivery Solutions for Wound Management: Innovations and Implementation Barriers," *Drug Metabolism and Bioanalysis*, 2026, doi: <https://doi.org/10.2174/0118723128406161251208194426>.
108. L. Ding, P. Kshirsagar, P. Agrawal, and D. J. Murry, "Crossing the Blood-Brain Barrier: Innovations in Receptor- and Transporter-Mediated Transcytosis Strategies," (in eng), *Pharmaceutics*, vol. 17, no. 6, May 28 2025, doi: 10.3390/pharmaceutics17060706.
109. M. Kothari *et al.*, "A Comprehensive Review of Monoclonal Antibodies in Modern Medicine: Tracing the Evolution of a Revolutionary Therapeutic Approach," (in eng), *Cureus*, vol. 16, no. 6, p. e61983, Jun 2024, doi: 10.7759/cureus.61983.
110. L. Wang, L. Ma, Z. Gao, Y. Wang, and J. Qiu, "Significance of gene therapy in neurodegenerative diseases," (in eng), *Front*

- Neurosci*, vol. 19, p. 1515255, 2025, doi: 10.3389/fnins.2025.1515255.
111. F. Nappi, "Non-Coding RNA-Targeted Therapy: A State-of-the-Art Review," (in eng), *Int J Mol Sci*, vol. 25, no. 7, Mar 24 2024, doi: 10.3390/ijms25073630.
  112. M. Gomes, M. J. Ramalho, J. A. Loureiro, and M. C. Pereira, "Advancing Brain Targeting: Cost-Effective Surface-Modified Nanoparticles for Faster Market Entry," (in eng), *Pharmaceutics*, vol. 17, no. 5, May 17 2025, doi: 10.3390/pharmaceutics17050661.
  113. A. Jiménez *et al.*, "Nanotechnology to Overcome Blood-Brain Barrier Permeability and Damage in Neurodegenerative Diseases," (in eng), *Pharmaceutics*, vol. 17, no. 3, Feb 20 2025, doi: 10.3390/pharmaceutics17030281.
  114. N. Parvin, M. Aslam, M. N. Alam, and T. K. Mandal, "Nanotechnology Driven Innovations in Modern Pharmaceutics: Therapeutics, Imaging, and Regeneration," (in eng), *Nanomaterials (Basel)*, vol. 15, no. 22, Nov 17 2025, doi: 10.3390/nano15221733.
  115. D. G. Gadhave *et al.*, "Nanotechnology-based advancements in Parkinson's therapy: Exploring animal models and clinical insights in neurodegenerative disorders," (in eng), *Ageing Res Rev*, vol. 115, p. 103026, Mar 2026, doi: 10.1016/j.arr.2026.103026.
  116. Z. Breijyeh and R. Karaman, "Comprehensive Review on Alzheimer's Disease: Causes and Treatment," (in eng), *Molecules*, vol. 25, no. 24, Dec 8 2020, doi: 10.3390/molecules25245789.
  117. H. M. Al-Kuraishy *et al.*, "Beyond amyloid plaque, targeting  $\alpha$ -synuclein in Alzheimer disease: The battle continues," (in eng), *Ageing Res Rev*, vol. 105, p. 102684, Mar 2025, doi: 10.1016/j.arr.2025.102684.
  118. T. E. Golde, "Disease-Modifying Therapies for Alzheimer's Disease: More Questions than Answers," (in eng), *Neurotherapeutics*, vol. 19, no. 1, pp. 209-227, Jan 2022, doi: 10.1007/s13311-022-01201-2.
  119. V. V. Goloborshcheva, V. G. Kucheryanu, N. A. Voronina, E. V. Teterina, A. A. Ustyugov, and S. G. Morozov, "Synuclein Proteins in MPTP-Induced Death of Substantia Nigra Pars Compacta Dopaminergic Neurons," (in eng), *Biomedicines*, vol. 10, no. 9, Sep 14 2022, doi: 10.3390/biomedicines10092278.
  120. T. Müller, "Update on the Present and Future Pharmacologic Treatment of Parkinson's Disease," (in eng), *Neurol Ther*, vol. 14, no. 5, pp. 1769-1781, Oct 2025, doi: 10.1007/s40120-025-00800-3.
  121. N. Phielipp and C. Henchcliffe, "Investigational Gene Therapies for Parkinson's Disease," (in eng), *CNS Drugs*, vol. 39, no. 8, pp. 725-737, Aug 2025, doi: 10.1007/s40263-025-01203-6.
  122. A. V. Ciurea *et al.*, "Unraveling Molecular and Genetic Insights into Neurodegenerative Diseases: Advances in Understanding Alzheimer's, Parkinson's, and Huntington's Diseases and Amyotrophic Lateral Sclerosis," (in eng), *Int J Mol Sci*, vol. 24, no. 13, Jun 28 2023, doi: 10.3390/ijms241310809.
  123. Z. Firdaus and X. Li, "Unraveling the Genetic Landscape of Neurological Disorders: Insights into Pathogenesis, Techniques for Variant Identification, and Therapeutic Approaches," (in eng), *Int J Mol Sci*, vol. 25, no. 4, Feb 15 2024, doi: 10.3390/ijms25042320.
  124. E. L. Feldman *et al.*, "Amyotrophic lateral sclerosis," (in eng), *Lancet*, vol. 400, no. 10360, pp. 1363-1380, Oct 15 2022, doi: 10.1016/S0140-6736(22)01272-7.
  125. S. K. Makkar, "Advances in RNA-based therapeutics: current breakthroughs, clinical translation, and future perspectives," (in eng), *Front Genet*, vol. 16, p. 1675209, 2025, doi: 10.3389/fgene.2025.1675209.
  126. R. Fatima *et al.*, "Amyloid- $\beta$  Clearance with Monoclonal Antibodies: Transforming Alzheimer's Treatment," (in eng), *Curr Protein Pept Sci*, vol. 26, no. 7, pp. 515-545, 2025, doi: 10.2174/0113892037362037250205143911.
  127. X. Shen, H. Li, B. Zhang, Y. Li, and Z. Zhu, "Tau-Targeted Therapeutic Strategies: Mechanistic Targets, Clinical Pipelines, and Analysis of Failures," (in eng), *Cells*, vol. 14, no. 19, Sep 26 2025, doi: 10.3390/cells14191506.
  128. F. H. Bazzari and A. H. Bazzari, "BACE1 Inhibitors for Alzheimer's Disease: The Past, Present and Any Future?," (in eng), *Molecules*, vol. 27, no. 24, Dec 12 2022, doi: 10.3390/molecules27248823.
  129. H. Li, X. Shen, B. Zhang, and Z. Zhu, "Biologics as Therapeutic Agents Under Perspective Clinical Studies for Alzheimer's Disease," (in eng), *Molecules*, vol. 30, no. 17, Aug 24 2025, doi: 10.3390/molecules30173479.
  130. [130] M. Alfai, R. A. Barker, and W. L. Kuan, "An update on immune-based alpha-synuclein trials in Parkinson's disease," (in eng), *J Neurol*, vol. 272, no. 1, p. 21, Dec 12 2024, doi: 10.1007/s00415-024-12770-x.
  131. L. Íñigo-Catalina, M. Ortiz-Cabello, E. Navarro, N. Esteras, L. Rancan, and S. D. Paredes, "Melatonin-Mediated Nrf2 Activation as a Potential Therapeutic Strategy in Mutation-Driven Neurodegenerative Diseases," (in eng), *Antioxidants (Basel)*, vol. 14, no. 10, Sep 28 2025, doi: 10.3390/antiox14101190.

132. L. Smith and A. H. V. Schapira, "GBA Variants and Parkinson Disease: Mechanisms and Treatments," (in eng), *Cells*, vol. 11, no. 8, Apr 8 2022, doi: 10.3390/cells11081261.
133. K. Ou, Q. Jia, D. Li, S. Li, X. J. Li, and P. Yin, "Application of antisense oligonucleotide drugs in amyotrophic lateral sclerosis and Huntington's disease," (in eng), *Transl Neurodegener*, vol. 14, no. 1, p. 4, Jan 21 2025, doi: 10.1186/s40035-025-00466-9.
134. Y. Lin *et al.*, "RNA-Targeting CRISPR/CasRx system relieves disease symptoms in Huntington's disease models," (in eng), *Mol Neurodegener*, vol. 20, no. 1, p. 4, Jan 13 2025, doi: 10.1186/s13024-024-00794-w.
135. B. G. Dogaru and C. Munteanu, "The Role of Hydrogen Sulfide (H<sub>2</sub>S) in Epigenetic Regulation of Neurodegenerative Diseases: A Systematic Review," (in eng), *Int J Mol Sci*, vol. 24, no. 16, Aug 8 2023, doi: 10.3390/ijms241612555.
136. T. Fang, G. Je, P. Pacut, K. Keyhanian, J. Gao, and M. Ghasemi, "Gene Therapy in Amyotrophic Lateral Sclerosis," (in eng), *Cells*, vol. 11, no. 13, Jun 29 2022, doi: 10.3390/cells11132066.
137. K. Shibuya, R. Otani, Y. I. Suzuki, S. Kuwabara, and M. C. Kiernan, "Neuronal Hyperexcitability and Free Radical Toxicity in Amyotrophic Lateral Sclerosis: Established and Future Targets," (in eng), *Pharmaceuticals (Basel)*, vol. 15, no. 4, Mar 31 2022, doi: 10.3390/ph15040433.
138. S. Kelliny, X. F. Zhou, and L. Bobrovskaya, "Alzheimer's Disease and Frontotemporal Dementia: A Review of Pathophysiology and Therapeutic Approaches," (in eng), *J Neurosci Res*, vol. 103, no. 5, p. e70046, May 2025, doi: 10.1002/jnr.70046.
139. K. Mayl, C. E. Shaw, and Y. B. Lee, "Disease Mechanisms and Therapeutic Approaches in C9orf72 ALS-FTD," (in eng), *Biomedicines*, vol. 9, no. 6, May 25 2021, doi: 10.3390/biomedicines9060601.
140. M. Vissers, J. Heuberger, and G. J. Groeneveld, "Targeting for Success: Demonstrating Proof-of-Concept with Mechanistic Early Phase Clinical Pharmacology Studies for Disease-Modification in Neurodegenerative Disorders," (in eng), *Int J Mol Sci*, vol. 22, no. 4, Feb 5 2021, doi: 10.3390/ijms22041615.
141. E. Luce and J. C. Duclos-Vallee, "Stem Cells and Organoids: A Paradigm Shift in Preclinical Models Toward Personalized Medicine," (in eng), *Pharmaceuticals (Basel)*, vol. 18, no. 7, Jul 1 2025, doi: 10.3390/ph18070992.
142. Z. Yang *et al.*, "Mitochondrial dynamics dysfunction and neurodevelopmental disorders: From pathological mechanisms to clinical translation," (in eng), *Neural Regen Res*, vol. 21, no. 5, pp. 1926-1946, May 1 2026, doi: 10.4103/nrr.Nrr-d-24-01422.
143. M. Valletta *et al.*, "Fluid biomarkers for neurodegenerative diseases: a comprehensive update," (in eng), *Alzheimers Res Ther*, vol. 18, no. 1, p. 12, Dec 20 2025, doi: 10.1186/s13195-025-01919-z.
144. S. Cohen, J. Cummings, S. Knox, M. Potashman, and J. Harrison, "Clinical Trial Endpoints and Their Clinical Meaningfulness in Early Stages of Alzheimer's Disease," (in eng), *J Prev Alzheimers Dis*, vol. 9, no. 3, pp. 507-522, 2022, doi: 10.14283/jpad.2022.41.